Skip to main content

Psoriatic arthritis

      The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.
      RT @uptoTate: "Healthier moms lead to healthier babies. This is how I frame the discussion regarding medications and PsA

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      "Healthier moms lead to healthier babies. This is how I frame the discussion regarding medications and PsA in my practice (with regard to reproductive health)." Dr. Talabi #ACR21 @RheumNow #RheumNow
      RT @synovialjoints: PsA impacts many aspects of life. PRO such as VAS pain
      and HAQ, are commonly assessed. The FACIT-Fat

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      PsA impacts many aspects of life. PRO such as VAS pain and HAQ, are commonly assessed. The FACIT-Fatigue scale, ranked the highest by patients. Personalized discussion is vital in assessment and shared decision making @RheumNow #ACR21 Abst#0751 https://t.co/gRfYK4sHc6 https://t.co/f5xjUnXsGQ
      RT @synovialjoints: With Deucravacitinib, a TYK2 inhibitor vs placebo, PsAID-12 and PsAID-9 scores were significantly im

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      With Deucravacitinib, a TYK2 inhibitor vs placebo, PsAID-12 and PsAID-9 scores were significantly improved versus baseline at Week 16 and other PROs showing a clear improvement in PsA-related impact @RheumNow #ACR21 Abst#0750 https://t.co/JbeSE2dO94 https://t.co/pH79dXCYSs
      RT @doctorRBC: 🌞😎🍣 Vitamin D and Omega-3 FA ⬇️ Risk of developing autoimmune disease
      1st prospective, rando

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      🌞😎🍣 Vitamin D and Omega-3 FA ⬇️ Risk of developing autoimmune disease 1st prospective, randomized, double blind, placebo controlled trial Vit D 2000IU and/or Omega 3-FA 1000mg ⬇️autoimmune disease by 25-30% #ACR21 #ACRBest @RheumNow Abs#957 https://t.co/7dODuplg7e https://t.co/GUKhYXbSXU
      RT @_Castillo_Pedro: Awesome presentation today from Dr. Cristina Ruiz-Romero on lipidomic profiles in RA vs PsA. Using

      Pedro Castillo _Castillo_Pedro

      3 years 10 months ago
      Awesome presentation today from Dr. Cristina Ruiz-Romero on lipidomic profiles in RA vs PsA. Using mass spectrometry, found differences in both synovial bx and fluid. Potentially useful lipid markers, more studies to follow. #ACR21 #ACRBest Abst#0946 @RheumNow https://t.co/KmWCPKijSx
      RT @_Castillo_Pedro: Interesting study with Dr. Julia Manasson on gut and skin microbiome in monozygotic twins discordan

      Pedro Castillo _Castillo_Pedro

      3 years 10 months ago
      Interesting study with Dr. Julia Manasson on gut and skin microbiome in monozygotic twins discordant for psoriatic disease. (red = Psoriatic). Gut ruminococcus bromii virtually absent in psoriatic pts. Eager to see further studies! #ACR21 Abst#0944 @RheumNow https://t.co/zrZPBAjh5p
      RT @MeralElRamahiMD: Abst#0946 shows a distinct lipid profile in RA vs PsA synovium + synovial fluid.

      Sphingomyelins &

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 10 months ago
      Abst#0946 shows a distinct lipid profile in RA vs PsA synovium + synovial fluid. Sphingomyelins & phosphatidyl-cholines/ethanolamines had the greatest separation power to classify RA + PsA samples. These lipid markers may have clinical utility if validated. #ACR21 @Rheumnow https://t.co/ktKRypTtlE
      RT @MeralElRamahiMD: Do you use RAPID3 in PsA?

      Abst#0633 at #ACR21 shows a strong agreement between RAPID3 remission sc

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 10 months ago
      Do you use RAPID3 in PsA? Abst#0633 at #ACR21 shows a strong agreement between RAPID3 remission score w/ DAPSA + cDAPSA, esp when redefining RAPID3 categories. Is this practice △ing? With more studies to validate, yes, since RAPID3 is simpler! @RheumNow https://t.co/2q0FLeBSkC https://t.co/M3WDTGzEOT
      RT @doctorRBC: Monozygotic twin study in PsO patients showed a gut and skin microbiome difference compared to their "nor

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      Monozygotic twin study in PsO patients showed a gut and skin microbiome difference compared to their "normal" twin ⭐️Ruminococcus decreased/absent in gut flora of PsO ⭐️microbiome differences even in healthy PsO skin Abs#944 #ACR21 @RheumNow #ACRBest https://t.co/VlfVh5Kt3Y https://t.co/W0eSqi77lx
      D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.
      RT @DrPetryna: Abst0944 #ACR21 #ACRBest @RheumNow microbiom evaluation of MZ twins discordant for PSO reveals Ruminococ

      Olga Petryna DrPetryna

      3 years 10 months ago
      Abst0944 #ACR21 #ACRBest @RheumNow microbiom evaluation of MZ twins discordant for PSO reveals Ruminococcus bromii species significantly reduced & two pathways related to tetrahydrofolate biosynthesis upregulated in PSO twins compared to their unaffected siblings (p< 0.05) https://t.co/67ao0l23sI
      The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
      ×